Abstract
Introduction: Advances in cystic fibrosis (CF) therapy have resulted in improved survival and increasing treatment burden and costs. The economic impact of current treatment strategies for CF is poorly defined. Methods: The authors prospectively assessed direct medical costs (including hospitalizations, outpatient interventions, drugs, devices, dietetic products) in 165 consecutive CF patients (aged 5-39 years) seen between March and July 2009. Results: The mean annual cost/patient increased with age and lung disease severity from €4,164 in children aged 5 years to €30,123 in patients aged >5 years with severe lung disease (forced expiratory volume in 1 second [FEV1]
| Original language | English |
|---|---|
| Pages (from-to) | 165-175 |
| Number of pages | 11 |
| Journal | Advances in Therapy |
| Volume | 30 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Cystic fibrosis
- Forced expiratory volume
- Healthcare costs
- Lung disease
- Respiratory
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
Cite this
Cost of cystic fibrosis : Analysis of treatment costs in a specialized center in Northern Italy. / Colombo, Carla; Daccò, Valeria; Alicandro, Gianfranco; Loi, Silvana; Mazzi, Silvio; Lucioni, Carlo; Ravasio, Roberto.
In: Advances in Therapy, Vol. 30, No. 2, 2013, p. 165-175.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost of cystic fibrosis
T2 - Analysis of treatment costs in a specialized center in Northern Italy
AU - Colombo, Carla
AU - Daccò, Valeria
AU - Alicandro, Gianfranco
AU - Loi, Silvana
AU - Mazzi, Silvio
AU - Lucioni, Carlo
AU - Ravasio, Roberto
PY - 2013
Y1 - 2013
N2 - Introduction: Advances in cystic fibrosis (CF) therapy have resulted in improved survival and increasing treatment burden and costs. The economic impact of current treatment strategies for CF is poorly defined. Methods: The authors prospectively assessed direct medical costs (including hospitalizations, outpatient interventions, drugs, devices, dietetic products) in 165 consecutive CF patients (aged 5-39 years) seen between March and July 2009. Results: The mean annual cost/patient increased with age and lung disease severity from €4,164 in children aged 5 years to €30,123 in patients aged >5 years with severe lung disease (forced expiratory volume in 1 second [FEV1]
AB - Introduction: Advances in cystic fibrosis (CF) therapy have resulted in improved survival and increasing treatment burden and costs. The economic impact of current treatment strategies for CF is poorly defined. Methods: The authors prospectively assessed direct medical costs (including hospitalizations, outpatient interventions, drugs, devices, dietetic products) in 165 consecutive CF patients (aged 5-39 years) seen between March and July 2009. Results: The mean annual cost/patient increased with age and lung disease severity from €4,164 in children aged 5 years to €30,123 in patients aged >5 years with severe lung disease (forced expiratory volume in 1 second [FEV1]
KW - Cystic fibrosis
KW - Forced expiratory volume
KW - Healthcare costs
KW - Lung disease
KW - Respiratory
UR - http://www.scopus.com/inward/record.url?scp=84891658369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891658369&partnerID=8YFLogxK
U2 - 10.1007/s12325-013-0008-5
DO - 10.1007/s12325-013-0008-5
M3 - Article
C2 - 23397400
AN - SCOPUS:84891658369
VL - 30
SP - 165
EP - 175
JO - Advances in Therapy
JF - Advances in Therapy
SN - 0741-238X
IS - 2
ER -